The regulation of GH1 and IGF-1 release is under the influence of three pituitary hormones (GHRH, GHRL and SST), which act in an autocrine/paracrine fashion in the breast. By binding to their respective receptors, they control cell proliferation, differentiation and apoptosis in a GH1/IGF-1 dependent manner.
Introduction
The development of the normal breast and the initiation and progression of breast cancer are under the influence of endocrine hormonal growth factors, that, when produced locally, can act in an autocrine/paracrine fashion (1) . During the last decade, research has revealed an important role of the growth-hormone 1 (GH1)/insulin-like-growth factor-1 (IGF-1)-axis on cell proliferation, differentiation and apoptosis and further on breast cancer development. We have shown earlier that polymorphisms in the genes along this axis contribute to breast cancer risk (2) (3) (4) . The contribution of genetic factors in the regulation of average daily GH1 secretion is about 27% (5) . Thus, polymorphisms in the genes regulating GH1 release may affect the risk of breast cancer. GH1, which stimulates the production of IGF-1, is produced under the stimulatory influence of growth-hormonereleasing hormone (GHRH) and ghrelin (GHRL), whereas somatostatin (SST) inhibits its production (1) . Elevated serum levels of GH1 and IGF-1 increase the risk of breast cancer (6) (7) (8) and transgenic mice overexpressing GH1 develop mammary adenocarcinomas (9) .
In addition, lit/lit mice, harbouring a mutation in the GHRH gene, have dramatically reduced GH1 and IGF-1 levels and a reduced growth of mammary tumour transplants (10) .
Biologically active GHRH has been found to be overexpressed in breast tumours (11) .
Tumour cell proliferation can be inhibited by applying GHRH antagonists that act either indirectly through the suppression of the GH1/IGF-1 axis or directly through suppression of the autocrine/paracrine production of IGF-1 (12) . GHRH mediates signalling through its receptor, GHRHR. Several splice variants of the GHRHR exist in various cancers and they are supposed to mediate the antiproliferative effects of GHRH antagonists (13) . The at Pennsylvania State University on February 21, 2013 http://carcin.oxfordjournals.org/ Downloaded from levels of GHRHR mRNA vary sex-specifically, and a significant inhibition of the GHRHR promoter has been observed by β-estradiol (14) .
Ghrelin (GHRL) belongs to the class of growth hormone secretagogues (GHS) that initially have been developed as synthetic molecules to stimulate the release of GH1.
GHRL has been identified as the only naturally occurring GHS (15). In vitro, GHRL stimulates GH1 release more potently than GHRH although these two hormones are thought to act in a synergistic way (16) . GHRL enhances appetite and is involved in obesity (15). As obesity is a risk factor for several cancers, including breast cancer (17) , GHRL may play an important role in cancer development. The effects of GHRL are mediated via the GHS receptor (GHSR) that is present in well-differentiated breast tumours. GHSR occurs as 2 splice variants with GHSR1a being the only one to show biological activity (15). GHSR 1a is expressed in normal and malignant breast tissue, while the GHSR1b isoform is exclusively present in breast carcinomas (18) . Transgenic female rats with an attenuated GHSR protein expression show reduced IGF-1 and GH1 levels (19) .
In contrast to GHRH and GHRL, SST inhibits the release of GH1 and further IGF-1 and decreases the rates of cell growth and proliferation. In tumours, SST not only blocks hormone hypersecretion but also causes variable degrees of tumour shrinkage (20) . Since SST has a short half-life of 1-3 minutes, SST analogues are used to block GHRH induced GH1 secretion and to inhibit cell proliferation (21) . Additionally, clinical studies have demonstrated a reduction in IGF-1 gene expression and serum IGF-1 levels after treatment of breast cancer patients with SST analogues (21) . The biological effects of SST are mediated directly through a family of five specific high affinity G protein-coupled receptors termed SSTR1-5. Although the different SSTR subtypes are structurally 40% to are found in some tumours. During cancer progression, the receptor expression is often lost (1, 20) .
In this study, we analysed the GHRH, GHRHR, GHRL, GHSR, SST and SSTR2 gene regions for published polymorphisms and dinucleotide repeats in order to find a possible association with breast cancer risk. We used a Polish breast cancer cohort and confirmed the positive findings in an independent German population.
Material and Methods

Subjects
The analyses were performed on genomic DNA with 405 Polish familial and early age breast cancer cases (mean age 46 years, range 22-81) and 460 regionally and ethnically matched female controls (mean age 42 years, range . The inclusion criteria were (i) at least 2 first-degree relatives with breast and/or ovarian cancer regardless of age, (ii) breast cancer diagnosed below the age of 35 without family history, (iii) bilateral breast cancer regardless of the family history, (iv) breast and ovarian cancer diagnosed in one patient regardless of the family history and (v) breast cancer diagnosed below 50 years of age regardless of family history (22) . The subjects corresponding to criteria (i)-(iv), 220 cases, were collected during the years 1997 to 2002 by the Chemotherapy Clinics and the Genetic Counselling Service (Gliwice, Poland) and the subjects corresponding to criteria were tested for 4 founder mutations in BRCA1 and 2 in BRCA2 and were found to be negative. These mutations account for more than 90% of the BRCA1/2 mutations in the Polish population (23) .
An independent population consisting of 393 German familial breast cancer cases (mean age 45 years, range 21-80) and 551 regionally and ethnically matched female controls (http://www.gdb.org/) and they were included into our analyses due to their potential influence on DNA and RNA stability (25) . Since SSTR2 is the most common SSTR in breast cancer, we restricted our analyses to this receptor subtype. 
Fragment analysis
For the analyses of the microsatellite repeats we used a fluorescent fragment analysis. The PCR amplification was performed as described above using the fluorescently labelled primers and annealing temperatures shown in table I. PCR products were visualised on ethidium bromide stained agarose gels (Invitrogen) and 1µl of the 1:10 diluted PCR product was added to 10µl HIDI-Formamide/ GeneScan ROX350 standard size marker (mixed according to the manufacturers instruction, Applied Biosystems). The mixture was denatured for 5 min at 95°C, loaded onto the ABI PRISM 3100 Genetic Analyser and analysed by the GeneMapper software version 3.0 (Applied Biosystems).
Statistical analysis
The observed genotype frequencies in the breast cancer cases and controls were tested for 
Results
Selection of polymorphisms
In order to select polymorphisms for the case-control study, we screened the GHRH, GHRHR, GHRL, GHSR, SST and SSTR2 gene regions in a small sample set of 23 breast cancer cases by sequencing.
In the GHRH gene, we only identified three rare SNPs, one in the coding region, one in intron 3 and one in the 3'UTR. Since the Leu75Phe SNP was the only one in the coding region and the PolyPhen tool predicted it as possibly damaging, we chose this SNP for further analyses. For the GHRHR gene, we confirmed three common SNPs in the promoter, out of which two were in 100% LD (C-771T and C-235T), and three SNPs in introns 1, 7 and 10. Additionally, we found 6 not reported SNPs in introns 1, 2, 5, 9, and 12. The SNPs leading to an amino acid change were too rare to be investigated further or did not exist. For further analyses, we chose the promoter SNPs C-261T and C-235T due to their location around an SP1 transcription factor binding site.
For GHRL, we confirmed 6 tightly linked SNPs in the promoter, 8 in intron 3 and one in the 3'UTR. Additionally, we confirmed the Leu72Met and Gln90Leu SNPs in the coding region but the Arg51Gln SNP was not detected in our small sample set. In preproghrelin, the Arg51Gln residue corresponds to the last amino acid of the mature GHRL product and an amino acid exchange thus may disturb the conversion of the peptide by endoproteases (26) . Leu72Met is outside the region of the mature GHRL; its function remains unclear.
PolyPhen prediction identified them as benign amino acid substitutions. Since these SNPs were in the same sequencing fragment, we decided to study them in our cohort.
Additionally, we analysed the promoter SNP G-1062C and the 3'UTR SNP T+673C in our larger cohort. In the GHSR gene, we confirmed the synonymous variants Gly57Gly
and Arg159Arg, which were investigated further, and 5 SNPs in the intronic sequences.
In the SST gene, we identified a so far unreported TC repeat in the promoter region 818bp
upstream of the translation start site. We confirmed the existence of 7 SNPs. Three SNPs out of 4 in intron 1 were in 100% LD as well as 2 SNPs in the 3'UTR. Additionally, we found a novel but rare Ala11Val SNP. We choose the TC promoter repeat, the SNPs IVS1 A+46G and 3'UTR A+22G for further analyses due to their potential impact on gene regulation. Furthermore, a TG repeat in intron 1 was investigated. In the SSTR2 gene, we found 3 not tightly linked SNPs in the promoter out of which we continued with the A- 167G variant due to its proven functional impact (27) . Besides, a TG repeat in the promoter, that is located in a region containing regulatory elements, was studied.
GHRHR C-261T is associated with a decreased breast cancer risk
We investigated the GHRH Leu75Phe variant as well as the GHRHR C-261T and C-235T
SNPs in the Polish breast cancer cohort. The observed allele frequencies were concordant with the ones reported for Caucasians in the NBCI SNP database. All genotype distributions followed HWE. We did not observe an effect for the GHRH Leu75Phe or the GHRHR C-235T SNPs on breast cancer risk (Table II) . For the GHRHR C-261T variant,
we observed an equally high protective effect for the heterozygous and homozygous T allele carriers (CT+TT vs. CC: OR 0.73, 95% CI 0.54-0.99, p = 0.04) (Table II) . In order to confirm this finding, we included an independent German population to our study. Also here, the T allele frequency was lower among the cases than the controls, but the difference was not statistically significant. In a joint analysis of the two populations, we Table II ).
GHRL haplotypes are associated with breast cancer risk
We investigated 4 SNPs in GHRL (G-1062C, Arg51Gln, Leu72Met and 3'UTR T+673C) and 2 SNPs in GHSR (Gly57Gly and Arg159Arg). All observed allele frequencies agreed with the ones published among Caucasians (NCBI SNP database). In the GHRL gene, although we did not detect the Arg51Gln SNP in our initial screening, the variant allele was present in 7% of the Polish cases and 5% of the Polish controls. We did not find any differences in the allele or genotype distributions for any of the four studied SNPs between the cases and the controls (Table III) . In the haplotype analysis, we found a small haplotype effect using logistic regression analysis (p = 0.07). A statistically significant protective effect was observed for the rare haplotypes GGAC and GGAT (Table III) (Table III) . Adjustment for age did not change the results.
SST polymorphisms are associated with a decreased breast cancer risk
We identified a novel TC repeat 818bp upstream of the translation start site in the putative SST promoter. Either 7 or 10 TC repeats were present. We investigated this polymorphism in the Polish cohort and observed a significantly decreased risk of breast cancer among the 10 TC repeat carriers (OR 0.65, 95% CI 0.44-0.96, p = 0.02). This effect was stronger in women above the age of 50 (OR 0.33, 95% CI 0.14-0.76, p = 0.004, Table IV) .
Similarly, the SNP in intron 1 (IVS1 A+46G), that was found to be in 94% LD with the TC repeat, showed a decreased OR in all women and a decreased breast cancer risk in women above the age of 50 (OR 0.39, 95% CI 0.18-0.87, p = 0.01, Table IV ). We also investigated these SNPs in the German cohort and observed a slightly decreased OR among women above the age of 50 and no effect among all women. In a joint analysis, we observed a protective effect for women above the age of 50 with a borderline significance.
Haplotype analyses with these two polymorphisms did not show any overall effect in Polish women (p = 0.11). However, the haplotype effect was significant in women above the age of 50 (p = 0.03) due to the protective effect of the 10G haplotype (OR 0.37, 95%
CI 0.17-0.80, p = 0.005, Table IV promoter revealed no effect on breast cancer risk (Table IV) . 
Discussion
The regulation of the synthesis and secretion of GH1 is multifactorial, but the predominant regulators are the hypothalamic hormones GHRH and GHRL, which stimulate GH1 release, and SST, which exerts inhibitory influences (1). In return, GH1, and also IGF-1, can act to inhibit GH1 secretion directly and indirectly by suppressing GHRH release and stimulating SST production (16) . Local production in the target tissues, such as the breast, has been revealed for all these hormones, facilitating their action in an autocrine/paracrine manner.
We investigated the effect of a total of 12 SNPs and 3 dinucleotide repeats in the genes encoding GHRH, GHRL, SST and their receptors on the risk of breast cancer. We included familial and early onset cases to our study because it has been shown earlier that selection of cases based on the family history of the same disease increases the power to detect lowpenetrance variants (28, 29) . With the present sample size, we had a power of 90% to detect an OR of 0.50 with a variant genotype frequency of 0.20 in the control population.
In the analyses of the subpopulations consisting of women above and under the age of 50, the power was lower. As another issue, a case-control association study with multiple SNPs or haplotypes in multiple genes represents a statistical multiple comparisons problem. Even though there are several methods for handling multiple comparisons in molecular epidemiology studies, no standard approach has been universally adopted (30).
In addition, it is unclear, how the biological relevance of a SNP should be taken into account. We did not correct for multiple comparisons, but we used two independent cohorts to confirm our findings. Additionally, we also studied if the effect of a SNP was carried by a haplotype, which would increase the reliability of the results. From the SNPs analysed in the GHRH and GHRHR genes, only the C-261T SNP in the GHRHR gene was associated with the risk of breast cancer. The -261T allele consistently correlated with a significantly a decreased OR and the effect was traced to a haplotype carrying the T allele. The C-261T SNP lies within a fragment that is necessary for the positive regulation of GHRHR transcription and expression (14) . It is located next to a SP1 transcription factor binding site which may influence transcription due to a conformational change.
In the GHRL gene, individual SNPs did not show any effect on the risk of breast cancer but we observed a protective effect for three rare haplotypes. From the SNPs involved in the haplotypes, G-1062C is a tagging SNP for the promoter (31, 32) and the Arg51Gln SNP changes the last amino acid of the mature peptide, which may lead to an altered protein cleavage. The Arg51Gln and Leu72Met SNPs have been associated with obesity and altered hormone levels (26, 33) , although further studies have not confirmed these associations (34) (35) (36) (37) . The 3'UTR T+673C SNP may affect mRNA stability and expression. Although a general haplotype effect was seen and the haplotype analysis revealed that the three rare haplotypes CGCT (5%), GGAC (1%) and GGAT (1%) were more frequent in the controls than the cases, no consistency in the presence of variant In the SST gene, we found a novel TC repeat in the SST promoter that contained either 7 or 10 TC repeats. This polymorphism was in 94% LD in the Polish cohort and in 97% LD in the German cohort with a SNP in intron 1 (IVS1A+46G) that may also influence gene regulation. A recent study identified the IVS1+46G allele to be associated with an increased breast cancer risk (38) . In our study, both the 10TC repeat and the IVS1 +46 G alleles and their joint haplotype were associated with a decreased breast cancer risk in the Polish women, especially among those above 50 years of age. However, we could not confirm the effect in the independent German population, even though the ORs were marginally decreased among women over the age of 50 years. Unfortunately, no characterization of the SST promoter has been reported so far. However, our search in the In the SSTR2 gene, the first exon is non-coding and the whole region up to the translation start often is referred to as the promoter sequence (39). We investigated a TG repeat polymorphism 4114bp upstream of the translation start site, immediately downstream of the non-coding exon 1, and identified the 21/21 genotype as a protective factor for breast cancer. This polymorphism resides in the promoter region that has been identified to contain regulatory elements, including an estrogen response element (39) . A study on sporadic breast cancer did not find any effect of the SSTR2 repeat polymorphism on breast . This SNP is associated with decreased promoter activity, but it was not associated with pancreatic cancer in a study consisting of 22 cases and 50 controls (27) . Another study found no differences in serum levels of GH1 and IGF-1 for -167G allele carriers and this genotype was not associated with acromegaly (41) . A recent study identified a marginally increased breast cancer risk, but only in heterozygotes for this SNP (38) . We did not observe any effect of this SNP on breast cancer risk.
In summary, we investigated the effect of polymorphisms in the GHRH, GHRHR, GHRL, 
